Dabrafenib Mesylate and Mircette
Determining the interaction of Dabrafenib Mesylate and Mircette and the possibility of their joint administration.
In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.
Consumer:Dabrafenib may reduce the blood levels and effects of ethinyl estradiol, which may make it less reliable as a form of birth control. Alternative or additional methods of birth control should be used during treatment with dabrafenib to avoid unintended pregnancy. This is particularly important because dabrafenib may cause harm in the unborn child. Talk to your gynecologist or other healthcare professional for help in selecting an effective method of birth control that is best for you. If you take hormone replacement for menopause, you should contact your doctor if you experience increased frequency or worsening of your symptoms such as hot flashes, vaginal dryness, or abnormal bleeding. It is important to tell your doctor about all other medications you use, including vitamins and herbs. Do not stop using any medications without first talking to your doctor.
Professional:ADDITIONAL CONTRACEPTION RECOMMENDED: Coadministration with dabrafenib may decrease the plasma concentrations and efficacy of contraceptive hormones. The mechanism is dabrafenib induction of CYP450 3A4, the isoenzyme primarily responsible for the metabolic clearance of sex hormones.
MANAGEMENT: Hormonal contraceptives, including oral, injectable, transdermal, and implantable forms, may not be reliable during concomitant therapy with dabrafenib. Because use of dabrafenib may cause fetal harm, it is particularly important that patients not become pregnant during treatment. Female patients of reproductive potential should use a highly effective, non-hormonal method of contraception during treatment and for 4 weeks after treatment. Input from a gynecologist or similar expert on adequate contraception, including emergency contraception, should be sought as needed. Intrauterine systems are unlikely to be significantly affected because of their local action.
- Faculty of Sexual & Reproductive Healthcare "FSRH Clinical Guidance: Drug Interactions with Hormonal Contraception. Available from: URL: file:///C:/Users/df033684/Downloads/ceuguidancedruginteractionshormonal.pdf." ([2012, Jan 1]):
- "Product Information. Tafinlar (dabrafenib)." GlaxoSmithKline, Research Triangle Park, NC.
Generic Name: dabrafenib
Brand name: Tafinlar
Synonyms: Dabrafenib
Generic Name: desogestrel / ethinyl estradiol
Brand name: Azurette, Cyclessa, Desogen, Isibloom, Kariva, Mircette, Reclipsen, Apri, Bekyree, Caziant, Ortho-Cept, Solia, Cesia, Cyred
Synonyms: n.a.
In the course of checking the drug compatibility and interactions, data from the following reference sources was used: Drugs.com, Rxlist.com, Webmd.com, Medscape.com.
- Dabrafenib Mesylate-Mircette Oral
- Dabrafenib Mesylate-Mirena
- Dabrafenib Mesylate-Mirena (52 MG)
- Dabrafenib Mesylate-Mirtazapine
- Dabrafenib Mesylate-Mirtazapine Orally Disintegrating Tablets
- Dabrafenib Mesylate-Mirtazapine Tablets
- Mircette-Dacarbazine
- Mircette-Dacarbazine Intravenous, Injection
- Mircette-Daclatasvir
- Mircette-Daclatasvir Dihydrochloride
- Mircette-Daclizumab
- Mircette-Daclizumab Subcutaneous